<DOC>
	<DOC>NCT02060188</DOC>
	<brief_summary>The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in patients with colon cancer that has come back or has spread, and who have a specific biomarker in their tumors.</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread</brief_title>
	<detailed_description>Allocation: The Microsatellite Instability High (MSI-High) and C4 Cohort Parts of the trial are Non-randomized, The Non-MSI high Dose Escalation Phase part of the trial contained a randomized portion</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Daratumumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Men and women â‰¥ 18 years of age Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 Histologically confirmed recurrent or metastatic colorectal cancer Measurable disease by CT or MRI Testing for MSI Status (by an accredited lab) 1. Subjects with microsatellite instability high (MSIH) tumors will enroll in the MSIH Cohort (mStage and cStage groups), the C3 Cohort, and the C5 Cohort. 2. Subjects with phenotypes that are nonmicrosatellite instability high (nonMSIH) will enroll in the non MSIH Safety Cohort and the C6 Cohort. Adequate organ function as defined by studyspecific laboratory tests Must use acceptable form of birth control throughout the study. After the final dose of study drug, an acceptable form of birth control must be used for 23 weeks for women of childbearing potential (WOCBP) and 31 weeks for men who are sexually active with WOCBP Signed informed consent Willing and able to comply with study procedures Subjects enrolled into the C3 Cohort must have not had treatment for their metastatic disease Active brain metastases or leptomeningeal metastases are not allowed. Prior treatment with an antiProgrammed Death Receptor (PD)1, antiPDL1, antiPDL2, antiCytotoxic TCell Lymphoma4 Antigen (CTLA4) antibody, or any other antibody or drug specifically targeting Tcell costimulation or immune checkpoint pathways Prior malignancy active within the previous 3 years except for locally curable cancers Subjects with active, known or suspected autoimmune disease Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of study drug administration Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>